Women who took the birth control shot for years are now asking a difficult question: did the pharmacy give them the brand-name Depo-Provera or a generic version, and does this effect their ability to file a lawsuit? It is a fair question, and one that matters for any woman considering a Depo-Provera meningioma lawsuit. 

Many patients never gave the answer a second thought at the time. The shot worked the same way regardless of which manufacturer made it, and most healthcare providers do not distinguish between brand and generic when administering the injection. But in the current litigation, the distinction does matter, and it matters in ways that are not always obvious to women who only learned about the meningioma connection after their diagnosis. 

If you or a loved one used Depo-Provera and were diagnosed with a meningioma brain tumor, the lawyers at Hissey Mulderig & Friend can help you sort out whether your history of use, brand or generic, supports a claim.  

Find out whether you qualify or start your claim today by calling our office toll-free at 1-866-806-8117, or by filling out the free Depo-Provera claims submission form located at the top of this page. 

What is Medroxyprogesterone Acetate?

Depo-Provera is the brand name for medroxyprogesterone acetate, often shortened to MPA. It is a long-acting injectable contraceptive given once every three months. Pfizer manufactures the brand-name versions, including Depo-Provera CI (the 150 mg intramuscular injection) and Depo-SubQ Provera 104 (a lower-dose subcutaneous injection). 

The active ingredient is identical across the brand and the generic versions. That is the design of generic drug approval: same active ingredient, same dose, same route of administration. The differences sit in the labeling, the manufacturer, and the regulatory history. 

When Generic MPA Injections Entered the Market 

The brand Depo-Provera contraceptive injection was approved by the U.S. Food and Drug Administration in 1992 under New Drug Application 020246. For more than a decade after that, Pfizer and predecessor Upjohn were effectively the only source of the injectable contraceptive in the United States. 

That changed in July 2004, when the FDA granted final approval for the first generic version of the medroxyprogesterone acetate injectable suspension, manufactured by Teva Pharmaceutical Industries. Teva began shipping single-dose vials in September 2004 and received approval for the pre-filled syringe presentation later that fall.  

Other companies, including Greenstone, a Pfizer subsidiary that markets authorized generics, have also distributed generic MPA injections under separate labels. 

The practical takeaway: before 2004, women who received the Depo shot in the United States almost certainly received the brand-name Pfizer product, because no FDA-approved generic equivalent of the injection existed. After 2004, the market included both brand and generic versions, and the product a patient received depended on the pharmacy or clinic that filled the prescription. 

Why the Lawsuits Against Depo-Provera Focus on Pfizer

The current Depo-Provera multidistrict litigation, pending in the U.S. District Court for the Northern District of Florida, names Pfizer and its corporate predecessors as the primary defendants. The legal theory is that Pfizer, as the company that developed the drug and held the original New Drug Application, was responsible for studying the risk of meningioma and adding an appropriate warning to the label. Background on the federal case is available in the firm’s MDL explainer. 

A meningioma warning did not appear on the U.S. label until December 2025, when the FDA approved a labeling change for Depo-Provera CI and Depo-SubQ Provera 104. The new language states that cases of meningioma have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use, and instructs prescribers to monitor patients for signs and symptoms of meningioma. The label change applies to the Pfizer-branded injectables. The FDA had earlier declined Pfizer’s request to apply the warning more broadly to all MPA-containing products. 

Plaintiffs cite research dating back decades, including a 2024 study published in the BMJ that found women with prolonged use of injectable medroxyprogesterone acetate had roughly 5.5-fold higher odds of intracranial meningioma requiring surgery compared with controls. For a closer look at the science, see the firm’s overview of what the medical research actually shows. 

Case Criteria for Filing a Depo-Provera Claim 

Women who used the birth control shot may be eligible to file a lawsuit and receive compenation if they meet the following criteria: 

1. At least one year of brand Depo-Provera use. A full year of use is typically four injections, given once every three months. This minimum reflects the research connecting prolonged exposure to meningioma risk. 
   

2. Brand use prior to 2004. Because the first generic injectable was not approved until July 2004, use of the Depo shot before that date is strong evidence of brand-name exposure. This is not a hard cutoff, but it is a useful indicator the firm relies on to confirm brand exposure. 
   

3. Diagnosis of cerebral meningioma after at least one year of brand use. The date of diagnosis itself is not the issue, as long as the diagnosis came after the one-year exposure threshold. Meningiomas can develop years or even decades after the relevant period of use. A diagnosis from 1992 or 2018 may both support a claim. 
   

4. Continued generic use is acceptable. Many women started on brand Depo-Provera in the 1990s or early 2000s and continued the shot for years afterward. As long as a woman had at least one year of brand-name use, subsequent years on the generic do not disqualify her case. 

Legal Options for Generic Birth Control Shots Users

Women who only received generic medroxyprogesterone acetate injections, with no documented brand-name use, face a more difficult path under current law.  

Federal preemption doctrine, as set out by the U.S. Supreme Court in cases involving generic drug labeling, has historically limited the claims a plaintiff can bring directly against the manufacturer of a generic medication. 

In practice, many women who started using the Depo shot in the 1990s or before 2004 did receive the brand-name product, even if later refills were dispensed as generic. If you are unsure which version you received, the firm can help.  

Documentation strategies and how to reconstruct a long history of use are covered in detail in the companion post on proving Depo-Provera use without complete records.  

Background on the underlying medical science is available on the firm’s pages on the Depo shot and meningioma connection and on meningioma risks for women who used the birth control shot. 

Contact An Attorney and Start Your Depo-Provera Claim

If you or a loved one used Depo-Provera and were diagnosed with a meningioma brain tumor, you may be eligible to file a lawsuit and receive compensation, even if a portion of your use was the generic version of medroxyprogesterone acetate rather than the brand-name product. 

The lawyers at Hissey Mulderig & Friend work on a strict contingency basis. This means you will never pay legal fees or other costs associated with filing a lawsuit unless we are able to successfully recover damages in your claim. 

Contact Hissey Mulderig & Friend today to learn more about your legal options and whether you qualify to pursue compensation for your injuries after using Depo-Provera.  

You can reach us by calling our office toll-free at 1-866-806-8117, or by sending us a message using the free claims submission form located at the top of this page.